Anti-sclerostin antibody treatment has recently been licensed as a monthly injection for treating osteoporosis (Evenity), a condition in which bones become fragile and more susceptible to fracture. Though effective at treating osteoporosis, concerns have been raised that Evenity increases the risk of developing cardiovascular disease (CVD) and stroke, either via a direct effect on arteries, or by modifying associated risk factors. This project aims to examine this question, by studying whether circulating levels of sclerostin are related to CVD end-points, related phenotypes and risk factors. This will be achieved by examining these relationships in a range of independent cohorts, including ALSPAC. Furthermore, we aim to triangulate our findings by Mendelian Randomisation, using a genetic instrument for circulating sclerostin which we recently published and are currently refining.